




Investigation of cellular responses to specific protein haptentation by low molecular weight chemical sensitisers

---


Dr Alexander Lester

# Introduction – Adverse Outcome Pathway

1 Endogenous protein modification (haptentation) following cell internalisation




3 Peptide antigen presentation on cell surface for dendritic cells





2 Cellular response following exposure

4 Dendritic cell activation and migration to lymph nodes




5 T cell activation, proliferation and differentiation


Type 1 immune response – skin sensitisers




Type 2 immune response – respiratory sensitisers




# Cell Lines & Chemical Sensitisers




**HaCaT**  
Keratinocytes




2-4-Dinitrochlorobenzene | **DNCB**  
(Skin Sensitiser)




Diphenylcyclopropanone | **DPCP**  
(Skin Sensitiser)




**A549**  
Alveolar Epithelial Cells



Phthalic Anhydride | **PA**  
(Respiratory Sensitiser)




Toluene 2,4-Diisocyanate | **TDI**  
(Respiratory Sensitiser)







**16HBE14o-**  
Bronchial Epithelial Cells

# Cell Viability Profiles After Sensitisation




# Dual Isotope Labelling LC-MS/MS Technique




Adapted from: Parkinson *et al.* Stable Isotope Labeling Method for the Investigation of Protein Haptenation by Electrophilic Skin Sensitisers. *Toxicological Sciences*. 2014.

# Global Haptenome - Repertoire




# Global Haptenome - Residue Proportions


## DNCB




## DPCP




## PA




## TDI




DNCB  
n = 87




DPCP  
n = 24



PA  
n = 106




TDI  
n = 57




Haptenated Residue  
 C  
 K



# Immuno-peptidomics – Background




MHCI binds endogenous cytoplasmic peptide antigens of 8-10 amino acids in length




MHCII binds exogenous peptide antigens of 14-18 amino acids in length



**MHC class I**  
Present in all nucleated cells





**MHC class II**  
Present in professional antigen-presenting cells






# Immunopeptidomics – Workflow


1. Anti-MHC monoclonal antibody extraction weekly from bioreactors, with automated purification and quantification of pooled mAb.
2. Dual isotope labelling of living alveolar epithelial cell cultures
3. Immunoprecipitation
4. Immunopeptide elution and purification.
5. Tandem mass spectrometry analysis.




# Immunopeptidomics Results: Overview




Control Replicates




DNCB Replicates




PA Replicates



## Immunopeptide Length Distributions




# Immunopeptidomics Results: MHC I 9mers




HLA class I immunopeptidome: HLA-A\*25:01, A\*30:01, B\*18:01, B\*44:03, C\*12:03, C\*16:01

# Immunopeptidomics Results: MHC I 10mers




HLA class I immunopeptidome: HLA-A\*25:01, A\*30:01, B\*18:01, B\*44:03, C\*12:03, C\*16:01

## MS<sup>1</sup> Precursor peptide ion scan



## MS<sup>2</sup> Fragmentated peptide ion scan



PA Δ130 cyclised adduct haptentation of **senrin-specific protease 2 (SEN2)** lysine residue.

Protease catalysing essential functions of the SUMO pathway, with nuclear localisation and export signal motifs.

SUMOylation has recently emerged as an important regulator of oxidative stress and hypoxic response pathways (Filippopoulou *et al*, 2020).

Interplay of SUMOylation and immune signalling/development pathways with the potential to shape specificity and recognition of immune responses has recently been outlined (Sajeev *et al*, 2021).

Involvement here highlights pathways potentially driving the divergence in adverse outcome pathway models.

- Notable difference in dose response identified in cells exposed to skin & respiratory sensitiser chemicals *in vitro*.
- Novel protein haptentation targets identified with respiratory sensitiser chemicals. Provides haptentomes for comparison to those previously generated from similar studies with skin sensitisers.
- *In vitro* haptentation adheres to the Cys v Lys chemical reactivity duality typically observed *in chemico*.
- Characterisation of the A549 alveolar epithelial cell immunopeptidome identified a reproducible, novel haptentated immunopeptide (SENP2) after exposure to the respiratory sensitiser phthalic anhydride.

# Acknowledgements



Prof. Paul Skipp



Dr. Ben Nicholas



Dr. Andy Shapanis



Dr. Maja Aleksic



Dr. Erika Parkinson



Dr. Alistair Bailey



Dr. Ramya Rajagopal



Dr. Stella Cochrane

